Anti-Hypertensive Drugs - Brunei Darussalam

Brunei Darussalam

The Anti-Hypertensive Drugs market in Brunei Darussalam is projected to reach a revenue of US$0.69m in 2024.
It is expected to show an annual growth rate of -0.59% from 2024 to 2029, resulting in a market volume of US$0.67m by 2029.
In the global comparison, United States is anticipated to generate the highest revenue of US$12,290.00m in 2024.
Brunei Darussalam's market for anti-hypertensive drugs is witnessing a surge in demand due to the country's aging population and increasing prevalence of hypertension.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Brunei Darussalam has been experiencing steady growth in recent years.

Customer preferences: As the population in Brunei Darussalam ages, the demand for anti-hypertensive drugs has increased. The country has a high prevalence of hypertension, which is a major risk factor for cardiovascular disease. Patients are increasingly seeking out effective and affordable medications to manage their condition.

Trends in the market: The market for anti-hypertensive drugs in Brunei Darussalam is dominated by generic medications, which are more affordable than branded drugs. However, there is also a growing demand for newer, more innovative drugs that offer better efficacy and fewer side effects. This has led to an increase in the availability of newer drugs in the market.

Local special circumstances: Brunei Darussalam has a small population of just over 400,000 people. This means that the market for anti-hypertensive drugs is relatively small, and there are fewer players in the market. However, the government is committed to providing affordable healthcare to its citizens, and this has led to the availability of a wide range of generic medications.

Underlying macroeconomic factors: Brunei Darussalam has a high GDP per capita, which means that its citizens have greater purchasing power. This has led to an increase in demand for healthcare services, including anti-hypertensive drugs. The government has also invested heavily in healthcare infrastructure, which has improved access to healthcare services across the country. Additionally, the country has a stable political environment, which has encouraged foreign investment in the healthcare sector.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.